P3-178: Occurrence of brain metastases in locally advanced NSCLC treated with radical radiotherapy (RT)  by Hansen, Olfred et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S755
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Median survival (month) p
p53 positive 5,03 0,2 
p53 negative 8,2
Ki67 positive 5,3 0,5
Ki67 negative 8,4
EGFR positive 5,3 0,5
EGFR negative 8,2
 Median survival (months) p
PS = 0 11,8 10-6 
PS =1 4,1
PS = 2 1,6
Age less 59 years 5,4 0,9
Age > 59 years 8,2
Female 7,5 0,5
Male 5
N0 9,7 0,008
N1 1,3
N2 8,3
N3 5,2
Conclusions: At this time of the study, there was no relation between 
expression of p53, EGFR, cell proliferation deﬁned by ki67 and surviv-
al. Correlation between PS, nodes extension and survival is conﬁrmed. 
Larger and longer follow-up studies may be needed to determine the 
prognostic role of expression of those new factors in NSCLC.
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Essential role for intensity-modulated radiotherapy (IMRT) in 
post-pneumonectomy mediastinal radiotherapy for stage III-N2 
non-small cell lung cancer
Haasbeek, Cornelis J.; Spoelstra, Femke O.; Lagerwaard, Frank J.; van 
Sornsen de Koste, John R.; Verbakel, Wilco F.; Slotman, Ben J.; Senan, 
Suresh 
Department of Radiation Oncology, VU University Medical Center, 
Amsterdam, The Netherlands
Background: Postoperative radiotherapy (PORT) in completely 
resected NSCLC with mediastinal N2 metastases reduces the incidence 
of loco-regional recurrences. The LungART study is an international 
prospective trial to be activated in 2007, randomizing between PORT 
(54Gy) and observation. Although recent reports suggest that PORT 
could improve survival, a previous meta-analysis had suggested 
increased treatment-related mortality, underscoring the need to limit 
doses to the heart and lung using modern treatment techniques. IMRT 
is currently not permitted in the LungART trial due to concerns about 
radiation toxicity arising from an increase in lung volumes exposed to 
low doses. We performed a planning study to determine if dose-con-
straints for critical organs could be achieved in PORT after pneumonec-
tomy.
Methods: Conventional 3D (Eclipse TPS, Varian Medical Systems) 
and IMRT (Helios, VMS) planning techniques were compared in ﬁve 
post-pneumonectomy patients (3 right-sided and 2 left-sided). Both 
limited and extended target volumes were designed according to the 
LungART protocol. The limited target volume consists of the bron-
chial stump, ipsilateral hilus, nodal stations 4 and 7, and in the case of 
left sided tumors also stations 5-6. Extended volumes are used when 
stations 8-9 contain metastasis, and consist of the above, plus the para-
esophageal and pulmonary ligament nodes (stations 8 and 9). All target 
volumes were derived from 4-dimensional (4D) CT scans, incorporat-
ing movement. A 3D margin of 5 mm was added to derive planning 
target volumes (PTV). The planned dose was 54 Gy (1.8 Gy/ fraction), 
using the following constraints: maximum spinal cord dose 45 Gy; 
maximum dose of 35 Gy to ≤30% of the cardiac volume; maximum 
dose of 20 Gy to ≤15% of the lung volume. 
Results: For the limited PTVs, critical organ constraints were met in 
all cases for both conventional radiotherapy and IMRT. For extended 
PTVs, critical organ constraints could only be met using IMRT (Figure 
1). This could be achieved without increasing low dose lung volumes 
(V5). Using conventional techniques for the extended target volumes, 
cardiac doses signiﬁcantly exceeded the speciﬁed constraints.
Conclusions: The use of IMRT appears essential to reduce cardiac 
doses in patients whose PORT volumes include nodal stations 8 and 
9. The decision to exclude IMRT in the forthcoming LungART trial 
should be revised. Planning data on the beneﬁts of respiration-gated 
IMRT delivery for these patients will be available at the time of the 
meeting.
Figure 1: Dose levels (mean percentage in 5 patients) using either convention-
al radiotherapy or IMRT, in limited and extended target volumes. The maximal 
spinal dose was below 45Gy. Error bars represent minimum and maximum 
values.
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Occurrence of brain metastases in locally advanced NSCLC 
treated with radical radiotherapy (RT)
Hansen, Olfred; Hansen, Karin H.; Stolberg-Rohr, Anthi 
Odense University Hospital, Odense, Denmark
Occurrence of brain metastases (BM) is a major problem in NSCLC. 
To evaluate the inﬂuence on survival in locally advanced NSCLC 
treated with radical RT, a retrospective analysis was performed of the 
patients treated at our institution. 
Methods: From June 1995 to Feb. 2005 207 patients with non-resect-
able NSCLC stage IIB-IIIAB received radical 3-D conformal RT with 
a planned dose ≥60Gy/30 F. Data on BM were retrospectively obtained 
from the patient ﬁles. End points were occurrence of BM and survival. 
Min. follow-up was 24 months. 
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Results: Stage at RT: IIB 10 (5%), IIIA 69 (33%), IIIB+recurrent dis-
ease 128 (62%). Male/female ratio was 128 /79. The median and 2-year 
survival was 15.7 months and 34.3%. 45 cases of BM were observed. 
The median time to BM was 7.7 months. The actuarial risk of BM at 
2 years was 25.5%. In 69% of all BM (31 cases) it was the ﬁrst site of 
failure and in 10 cases BM remained the only site of failure. In logistic 
regression analyses female gender and adenocarcinoma were associated 
with higher risk of developing BM. The survival after diagnosis of BM 
was 2.8 months. The patient with BM being the ﬁrst site of recurrence 
had better prognosis than patients experiencing BM at a later stage (5.3 
vs. 2.0 months, p>0.0001). The prognosis after BM as ﬁrst failure were 
no worse than patients having other sites as ﬁrst distant failure (5.3 
vs. 4.9 months, p=0.7). If the patients, who died with BM as the only 
manifestation of recurrence, were censored at the time of death in the 
survival analysis, the median survival would increase by 1.4 months 
to 17.1 months, and the 2-year survival rate would increase by 1.7% to 
36.0%. 
In a Cox-multivariate analysis female gender, use of neoadjuvant che-
motherapy, and stage at RT was associated with poorer BM-RFS while 
adenocarcinoma was of borderline importance, and age and perfor-
mance status at RT were insigniﬁcant factors.
Conclusions: A signiﬁcant number of patients with locally advanced 
NSCLC, especially females and adenocarcinomas, experienced BM. 
The survival after diagnosis of BM as ﬁrst failure was no worse than 
patients experiencing other distant sites as ﬁrst failure, and the results 
indicate that PCI would add only little to survival
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Isotoxic hypofractionated radical radiotherapy for non-small cell 
lung cancer (NSCLC)
Hudson, Emma1 Button, Michael1 Wills, Lucy1 Fenwick, John2  
Macbeth, Fergus R.1 Lester, Jason F.1 
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Wirral, UK 
Background: Many patients presenting with localized/locally ad-
vanced NSCLC are considered unsuitable for surgery; a signiﬁcant pro-
portion of these may be suitable for radical radiotherapy (radiotherapy 
given with curative intent). 
Clinical data suggest that: 
1. There is a dose-response effect with radiotherapy (RT) in NSCLC.
2. Shortening overall treatment time (acceleration) may limit tumour 
repopulation and improve outcomes.
Accelerated hypofractionated RT shortens overall treatment time by 
using fewer, larger fractions compared to conventional RT and the regi-
men most commonly used in the UK for NSCLC is the hypofraction-
ated schedule of 55Gy in 20 fractions over 4 weeks.
Dose escalation can be achieved by keeping fraction number the same 
and increasing the dose per fraction. This maintains the beneﬁts of 
acceleration, potentially maximizing the beneﬁt of any increase in total 
dose. 
There are three dose-limiting organs at risk (OARs) in radical RT for 
NSCLC and treatment is designed to keep the dose to these within pre-
deﬁned limits; for lungs, mean normalized tissue dose <17Gy (NTD-
mean), spinal cord <44Gy and oesophagus <58.5Gy. 
Conventionally, the dose prescribed for all patients in a particular 
department is the same as long as OAR limits are not exceeded. Doses 
received by OARs vary greatly between patients depending on the 
size and position of the tumour. Therefore, in some patients it should 
be possible to increase the dose prescribed whilst staying within OAR 
dose limits. In others, where OARs lie adjacent to the tumour within 
the high dose planning target volume (PTV), dose escalation will be 
limited.
Methods: We conducted a retrospective review of 10 consecutive radi-
cal RT plans in patients prescribed 50-55Gy in 20 fractions delivered 
using 3DCRT to assess the feasibility of a prospective isotoxic dose 
escalation study. Doses were increased until the ﬁrst OAR dose limit 
was reached. None of the treatment plans were changed.
Results: In 5/10 patients, lung NTDmean was the ﬁrst dose limit 
reached, and theoretical prescribed doses ranged from 77-166Gy in 20 
fractions. In 2/10 patients oesophagus was the dose limit ﬁrst reached 
(theoretical prescribed doses 62Gy and 129Gy). In 1/10 patients, the 
cord limited the theoretical prescribed dose to 81Gy. 2/10 patients had 
oesophagus in the PTV, and no escalation was possible. The dose to the 
heart was insigniﬁcant in all cases.
Conclusions: Individualised dose escalated isotoxic radical RT to pre-
deﬁned safe OAR limits may improve outcomes. We will shortly be 
assessing the feasibility of this concept a prospective study. 
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Radical radiotherapy for non small cell lung cancer (NSCLC): can 
chemotherapy make the untreatable treatable?
Hudson, Emma; Johns, Catherine; Brewster, Alison E.; Hanna, Louise; 
Bailey, Hazel; Macbeth, Fergus R.; Lester, Jason F. 
Velindre Hospital, Cardiff, UK
Introduction: Patients with NSCLC who are not suitable for surgery 
can present with locally advanced, non-metastatic disease that is too 
large for radical radiotherapy (RT). In this situation chemotherapy can 
be used to reduce tumour size such that disease can be encompassed 
within a radical RT volume. To our knowledge there is no evidence in 
the literature to support this practice. We have conducted a retrospec-
tive review of patients initially presenting with tumours deemed too 
large for curative treatment who received radical RT following a good 
response to chemotherapy. 
Methods: Patients were identiﬁed using ISCO, an in-house electronic 
database of all cancer patients referred to Velindre hospital. Data were 
collected retrospectively through ISCO and review of the case notes. 
Survival was assessed using the log-rank method.
Results: Between March 1998 and August 2005, 15 patients were iden-
tiﬁed. There were 11 men (73%, median age 69 years) and 4 women 
(27%, median age 63.5 years). In total, 40% of patients were stage 3, 
27% stage 2, 33% stage 1. All patients received between 1 and 4(me-
dian 3) cycles of platinum-based chemotherapy. The Mean maximum 
tumour diameter pre chemotherapy was 7.5cm, and post chemotherapy 
was 5cm. All patients were planned using 2D or 3D conformal RT, and 
post chemotherapy volumes were used for planning. Patients either 
received CHART or 55Gy in 20 fractions. In total 26% of patients had 
a complete response to RT, 26% a partial response and 26% stable 
disease. Response was not recorded in 22% of patients.
Median overall survival (OS) was 18 months (95% CI 15-21 months). 
In total 47% of patients have relapsed locally and 20% (3/15) of pa-
tients developed brain metastases. In 2 patients the brain was the only 
site of relapse.
